Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA

References

• Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, Chang YY, Lai SL, Chen WH, Chen MC. Serial changes in platelet activation in patients after ischemic stroke: Role of pharmacodynamic modulation. Stroke 2004; 35(7)1683–1687
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004; 2(4)535–545
   PubMedGoogle Scholar
• Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010; 26(4)140–145
   PubMedGoogle Scholar
• Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 51–61
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56(12)919–933
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008; 336(7637)195–198
   PubMed Web of Science ®Google Scholar
• Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and metaanalysis. Am Heart J 2010; 160(3)543–551
   PubMed Web of Science ®Google Scholar
• Karazniewicz-Lada M, Danielak D, Glowka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother 2012; 13(5)663–683
   PubMed Web of Science ®Google Scholar
• Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106(2)191–202
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50(16)1541–1547
   PubMed Web of Science ®Google Scholar
• Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. Heart 2011; 98(4)343, author reply 343–4
   PubMed Web of Science ®Google Scholar
• Topcuoglu MA, Arsava EM, Ay H. Antiplatelet resistance in stroke. Expert Rev Neurother 2011; 11(2)251–263
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431)331–337
   PubMed Web of Science ®Google Scholar
• Ringleb PA, Bousser MG, Ford G, Bath P, Brainin M, Caso V, Cervera A, Chamorro A, Cordonnier C, Csiba L, et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25(5):457–507
   Google Scholar
• Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: From a theoretical to a practical perspective. Int J Endocrinol 2011; 2011: 742–759
   Web of Science ®Google Scholar
• Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample – The Funagata study. Metabolism 2008; 57(3)333–338
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, Kastrati A, Von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99(1)121–126
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, Von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53(10)849–856
   PubMed Web of Science ®Google Scholar
• Definition WHO, and diagnosis of diabetes mellitus and intermediate hyperglycemia;2006; Available from: http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7)412–419
   PubMed Web of Science ®Google Scholar
• Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, Von Beckerath N, Mehilli J. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8(8)1685–1693
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54(8)2430–2435
   PubMed Web of Science ®Google Scholar
• Yngen M, Ostenson CG, Hjemdahl P, Wallen NH. Meal-induced platelet activation in Type 2 diabetes mellitus: Effects of treatment with repaglinide and glibenclamide. Diabet Med 2006; 23(2)134–140
   PubMed Web of Science ®Google Scholar
• Yngen M, Ostenson CG, Li N, Hjemdahl P, Wallen NH. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001; 12(2)109–116
   PubMed Web of Science ®Google Scholar
• Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003; 92(11)1362–1365
   PubMed Web of Science ®Google Scholar
• Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, Vlassara H, Koschinsky T, Tschoepe D. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48(8)475–481
   PubMed Web of Science ®Google Scholar
• Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44(2)188–195
   PubMed Web of Science ®Google Scholar
• Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Heften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26(2)417–422
   PubMed Web of Science ®Google Scholar
• Braun OO, Amisten S, Wihlborg AK, Hunting K, Nilsson D, Erlinge D. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). Purinergic Signal 2007; 3(3)195–201
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52(24)1968–1977
   PubMed Web of Science ®Google Scholar
• Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279(5)3254–3264
   PubMed Web of Science ®Google Scholar
• Yngen M, Li N, Hjemdahl P, Wallen NH. Insulin enhances platelet activation in vitro. Thromb Res 2001; 104(2)85–91
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002; 25(7)1177–1184
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sakurai M, Miura K, Morikawa Y, Ishazaki M, Yoshita K, Kido T, Naruse Y, Nakagawa H. Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men. Diabetologia 2010; 53(9)1894–1902
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: The Bruneck study. Diabetes Care 2007; 30(2)318–324
   PubMed Web of Science ®Google Scholar
• Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davi G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48(12)2531–2538
   PubMed Web of Science ®Google Scholar
• Spectre G, Ostensen CG, Li N, Hjemdahl P. Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. Diabetes 2012; 61(9)2380–2384
   PubMed Web of Science ®Google Scholar
• Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55(1)202–208
   PubMed Web of Science ®Google Scholar
• Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006; 17(8)577–585
   PubMed Web of Science ®Google Scholar
• Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35(5)1147–1152
   PubMed Web of Science ®Google Scholar
• Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84(2)613–617
   PubMed Web of Science ®Google Scholar
• Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18(3)199–206
   PubMed Web of Science ®Google Scholar
• Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 2009; 105(3)379–387
   PubMed Web of Science ®Google Scholar
• Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1)35–41
   PubMed Web of Science ®Google Scholar
• Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, Kesmarky G, Czopf L, Toth K. Aspirin resistance: Possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 2006; 23(7)559–567
   PubMed Web of Science ®Google Scholar
• Knight CJ, Panesar M, Wilson DJ, Chronos NA, Patel D, Fox K, Goodall AH. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95(1)125–132
   PubMed Web of Science ®Google Scholar
• Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K, Bhatt DL. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke 2012; 43(9)2376–2381
   PubMed Web of Science ®Google Scholar